Overview Request Sample Pages Request Customization Download PDF
You are viewing: US Protein Expression Market analysis
Part of: Protein Expression Market (Global)

The US Protein Expression Market was valued at $1482.8 Million in 2026 and projected to reach to $2235.7 Million by 2031, representing a compound annual growth rate of 8.6%. The US protein expression market is poised for sustained growth through 2031, fueled by escalating demand for biopharmaceutical manufacturing capabilities and the development of next-generation therapeutic proteins.

US Protein Expression Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

US Protein Expression Market Trends and Insights

  • This expansion reflects the US healthcare sector's increasing demand for advanced biopharmaceutical manufacturing capabilities and recombinant protein production technologies.
  • The US market benefits from strong R&D investment, a mature biotechnology ecosystem, and regulatory frameworks that support innovation in protein therapeutics. Driving this 8.6% compound annual growth rate, the US protein expression market is fueled by rising adoption of mammalian and microbial expression systems across pharmaceutical companies and contract research organizations.
  • The US continues to lead in cell-based therapies, monoclonal antibody production, and personalized medicine applications.
  • Between 2026 and 2031, the US market will see accelerated investment in expression platform optimization, automation, and scalable manufacturing solutions to meet growing therapeutic demand..

Key Market Statistics

  • CAGR (2026-2031) 8.6% CAGR
  • Market Size, 2026 ~USD 1482.8 Million
  • Forecast, 2031 ~USD 2235.7 Million
  • Country US

US Protein Expression Market Overview

Market Valuation Growth :

The US protein expression market is valued at $1,482.8 million in 2026 and is projected to reach $2,235.7 million by 2031, representing a robust 8.6% CAGR driven by increased biopharmaceutical manufacturing demand.

Strong R&D Investment :

The US benefits from substantial government and private sector R&D funding, supporting innovation in recombinant protein production technologies and advanced expression systems across academic and commercial institutions.

Biopharmaceutical Manufacturing Leadership :

The US maintains a dominant position in global biopharmaceutical production, with protein expression technologies critical to developing monoclonal antibodies, therapeutic proteins, and biologics for domestic and international markets.

Mature Biotechnology Ecosystem :

A well-established network of biotech companies, contract manufacturers, and research institutions in the US creates a competitive landscape driving continuous technological advancement and market expansion.

US Protein Expression Market Dynamics

  • Increasing investments in cell and gene therapy, coupled with FDA approvals for novel biologics, will drive adoption of advanced expression systems.
  • The market will benefit from technological innovations in mammalian, microbial, and insect cell expression platforms, alongside growing outsourcing trends among pharmaceutical companies seeking specialized manufacturing partners. Regulatory support and favorable reimbursement policies for biopharmaceutical products will further accelerate market expansion.
  • The US market's growth trajectory will outpace global averages, reflecting the country's leadership in biotechnology innovation, substantial healthcare spending, and the presence of major pharmaceutical and biotech companies investing heavily in protein production infrastructure and capabilities..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • The US protein expression market will grow from $1,482.8M (2026) to $2,235.7M (2031) at an 8.6% CAGR.
    • The US leads in mammalian and microbial expression system adoption for biopharmaceutical manufacturing.
    • Strong R&D investment and regulatory support position the US as the dominant protein expression hub.
    • Automation and scalable manufacturing solutions will drive US market expansion through 2031.

    Protein Expression Market Report Scope

    Report Metric Details
    Base Year 2026
    Fastest Growing Segment SOFTWARE (Type)
    Forecast Period 2026–2031
    Growth Rate CAGR of 8.3% from 2026 to 2031
    Largest Segment PRODUCTS (Offering)
    Market Size Base Year (Billions) ~USD 5.13 (2026)
    Revenue Forecast (Billions) ~USD 7.65 (2031)
    Segments Covered Offering, Type, End User, Workflow, Scale Of Operation, Protein Modality, Application

    US Protein Expression Market Report Segmentation

    7 segment dimensions are covered across the global market.

    By Offering

    • Products
    • Services

    By Type

    • Algal & Plant-Based Expression Systems
    • Algal-Based Expression Systems
    • Analytical Instruments
    • Bacillus Systems
    • Baculovirus Systems
    • Bioreactors & Fermenters
    • Cell-Free Expression Systems
    • Cho Cell Systems
    • Chromatography & Purification Consumables
    • Chromatography Systems
    • Cld Services
    • Cloning & Mutagenesis Kits
    • Competent Cells
    • Consumables
    • Culture Media & Supplements
    • Custom Protein Expression Services
    • E. Coli Lysate-Based Systems
    • E. Coli Systems
    • Expression Kits
    • Expression Vectors & Plasmids
    • Filtration & Separation Consumables
    • Filtration Systems
    • Gene Synthesis & Cloning Services
    • Hek 293 Cell Systems
    • Insect Cell Expression Systems
    • Instruments
    • Kits
    • Liquid Handling & Automation Systems
    • Mammalian Cell Expression Systems
    • Other Cell-Free Expression Systems
    • Other Consumables
    • Other Insect Cell Expression Systems
    • Other Instruments
    • Other Kits
    • Other Mammalian Cell Expression Systems
    • Other Prokaryotic Expression Systems
    • Other Reagents
    • Other Yeast Expression Systems
    • Pichia Systems
    • Process Development & Scale-Up Services
    • Prokaryotic Expression Systems
    • Reagents
    • Saccharomyces Systems
    • Software
    • Transduction & Transfection Reagents
    • Yeast Expression Systems

    By End User

    • Academic & Research Institutes
    • Cros & Cdmos
    • Other End Users
    • Pharmaceutical & Biotechnology Companies

    By Workflow

    • Cloning & Transfection
    • Extraction, Purification, And Characterization
    • Transcription, Translation, And Post-Translational Modification (Ptm)

    By Scale Of Operation

    • Discovery & Research Scale
    • Preclinical & Characterization Scale
    • Process Development & Pilot Scale

    By Protein Modality

    • Enzymes & Catalytic Proteins
    • Monoclonal Antibodies & Derivatives
    • Other Proteins
    • Recombinant Therapeutic Proteins
    • Vaccines

    By Application

    • Diagnostic Applications
    • Industrial Applications
    • Research Applications
    • Therapeutic Applications

    US: PROTEIN EXPRESSION SERVICES MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES90.794.6105.5115.2125.7137.2149.7163.19.1
    OTHER END USERS24.42527.329.231.233.435.738.16.9
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES171177.9197.8215.6234.6255.5278.1302.38.8
    TOTAL286.1297.5330.6360.1391.5426.1463.5503.58.8

    US: PROTEIN EXPRESSION PRODUCTS MARKET, BY END USER, 2024–2031

    Segment20242025202620272028202920302031CAGR (%)
    ACADEMIC & RESEARCH INSTITUTES293.8306.2341372.3405.8442.7482.6525.49
    CROS & CDMOS332.6347.7388.3425.2464.7508.4555.8606.89.3
    OTHER END USERS242.9248.7272.1291.7312.2334.4357.8382.37
    PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES419.3434.6481.3522.5566.3614.4666.2721.28.4
    TOTAL1288.61337.31482.81611.717491899.92062.52235.78.6

    Target Audience

    • Biopharmaceutical Manufacturers : US-based and international pharma companies need detailed market insights to optimize protein expression manufacturing strategies, evaluate outsourcing partnerships, and plan capacity expansion in the American market.
    • Contract Manufacturing Organizations (CMOs) : CMOs operating in the US require market intelligence to identify client acquisition opportunities, benchmark service offerings, and strategically position their protein expression capabilities against competitors.
    • Biotech Investors & Venture Capitalists : Investment firms focused on US biotechnology need comprehensive market data to evaluate funding opportunities, assess portfolio company growth potential, and identify emerging segments within protein expression technologies.
    • Research Institutions & Universities : Academic centers and research organizations in the US need market insights to align research initiatives with commercial applications, secure funding, and understand industry demand for protein expression innovations.
    • Equipment & Technology Suppliers : Manufacturers of protein expression systems, bioreactors, and analytical instruments need US market data to identify customer segments, forecast demand, and develop targeted sales strategies for the American market.

    Key Companies in the US Protein Expression Market

    CompanyHQOwnershipStrongest segments
    PATHEON INCNetherlandsPrivate CompanyDrug Product Services (finished dosage manufacturing & packaging),Pharmaceutical Development Services,Drug Substance Services (small- and large-molecule APIs),
    NANOSTRING TECHNOLOGIES, INCUnited StatesPrivate CompanynCounter instruments and consumables (Pro, FLEX, SPRINT, CodeSets, panels, reagents),GeoMx DSP and spatial biology solutions,Prosigna and other in vitro diagnostic kits,
    BIOGENUnited StatesPublic CompanyMultiple Sclerosis therapies (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS-related),SPINRAZA and rare neuromuscular (SPINRAZA, QALSODY, SKYCLARYS),Alzheimer’s and neuropsychiatry (LEQEMBI, ZURZUVAE),
    SIGMA-ALDRICH CORPORATIONUnited StatesPrivate CompanyPharma and biopharma manufacturing (media, filtration, critical raw materials, safety testing),Research reagents and molecular biology (chemicals, biochemicals, functional genomics, protein biology),Analytical chemistry, diagnostics, and industrial microbiology,
    VIVA BIOTECH LTDChinaPublic CompanyDiscovery biology & structural biology services,Medicinal and synthetic chemistry & CADD,CDMO & CMC/filing services,
    CODEXIS, INC.United StatesPublic CompanyBiopharma process enzymes and custom engineering (CodeEvolver-based),ECO Synthesis and nucleic acid manufacturing solutions,Other life science and industrial enzyme applications,
    MAXCYTE, INCUnited StatesPublic CompanyExPERT ATx instruments and related consumables,ExPERT STx instruments and related consumables,ExPERT GTx instruments and related consumables,
    THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
    MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, bioprocessing, CDMO),Healthcare (oncology, neurology, fertility, rare diseases),Electronics (semiconductor and display materials, delivery equipment),
    DANAHER CORPORATIONUnited StatesPublic CompanyBiotechnology (bioprocessing and bioproduction),Life Sciences (research and analytical instruments, genomics),Diagnostics (clinical instruments and consumables),
    AGILENT TECHNOLOGIES, INC.United StatesPublic CompanyLife Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets,
    SARTORIUS AGGermanyPublic CompanyBioprocess solutions (bioreactors, cell culture, fluid management, process filtration),Analytical solutions (BLI, cytometry screening, PAT, live-cell imaging, SPR),Lab products and services (filtration, purification, lab water, weighing, pipettes, microbiological testing),
    GENSCRIPTHong KongPublic CompanyLife Science Services and Products,Biologics Development Services,Industrial Synthetic Biology Products,
    TAKARA BIO INC.JapanPrivate CompanyGenetic and cellular research reagents,Instruments and cellular analysis devices,In vitro diagnostics (including COVID-19),
    BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science Research Instruments and Reagents,Other / Software and Services,
    QIAGENNetherlandsPublic CompanySample technologies (extraction and purification consumables/instruments),PCR and enzymes (qPCR/dPCR instruments and reagents),Molecular diagnostic assays (TB, oncology, sexual and reproductive health, transplant/viral load),
    CHARLES RIVER LABORATORIESUnited StatesPublic CompanyResearch Models and Services,Discovery and Safety Assessment,Manufacturing Solutions,
    CORNING INCORPORATEDUnited StatesPublic CompanyOptical communications (fiber, cable, hardware, equipment),Display glass substrates (LCD/OLED),Specialty materials and mobile consumer electronics glass,
    LONZASwitzerlandPublic CompanyIntegrated Biologics (mammalian and drug product CDMO),Advanced Synthesis (small molecules, HPAPIs, ADCs, bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA),
    FUJIFILM HOLDINGS CORPORATIONJapanPublic CompanyHealthcare (medical systems, CDMO, pharma, regenerative, cosmetics/supplements),Electronics (display, semiconductor, image sensors, functional films, storage),Business Innovation (office equipment, document services, graphic communications),
    SYNGENE INTERNATIONAL LIMITEDIndiaPublic CompanyDiscovery Services (chemistry, biology, computational),Development Services (preclinical, CMC, clinical development),Biologics and Specialty Modalities,
    LGC LIMITEDSouth KoreaPublic CompanyEthylene-based synthetic resins (PE, EVA, LLDPE, UNIQABLE),Styrene-based resins (ABS, ASA, PS, EPS, SAN),Polycarbonate and engineering plastics (LUMID/LUXY, LUMILOY, LUPOL, LUPOY, etc.),

    PATHEON INC

    Patheon Inc is a Netherlands-based private company with 9,100 employees operating in the life sciences sector.

    NANOSTRING TECHNOLOGIES, INC

    NanoString Technologies, Inc is a United States-based private company founded in 2003 with 550 employees specializing in life sciences technology.

    BIOGEN

    Biogen is a United States-based public company founded in 1978 with 7,500 employees engaged in biotechnology and pharmaceutical development.

    SIGMA-ALDRICH CORPORATION

    Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees providing life sciences products and services.

    VIVA BIOTECH LTD

    Viva Biotech Ltd is a China-based public company founded in 2008 with 2,169 employees providing drug discovery and development services.

    CODEXIS, INC.

    Codexis, Inc is a United States-based public company founded in 2002 with 146 employees focused on enzyme engineering and biocatalysis.

    MAXCYTE, INC

    MaxCyte, Inc is a United States-based public company founded in 1998 with 91 employees specializing in cell engineering technology.

    THERMO FISHER SCIENTIFIC INC.

    Thermo Fisher Scientific Inc is a United States-based public company founded in 1956 with 125,000 employees serving the life sciences and laboratory sectors globally.

    MERCK KGAA

    Merck KGaA is a Germany-based public company founded in 1668 with 59,077 employees operating as a diversified pharmaceutical and chemical company.

    DANAHER CORPORATION

    Danaher Corporation is a United States-based public company founded in 1969 with 59,000 employees engaged in life sciences, diagnostics, and environmental solutions.

    AGILENT TECHNOLOGIES, INC.

    Agilent Technologies, Inc is a United States-based public company founded in 1999 with 18,000 employees providing analytical instruments and life sciences solutions.

    SARTORIUS AG

    Sartorius AG is a Germany-based public company founded in 1870 with 14,242 employees specializing in laboratory and bioprocess equipment.

    GENSCRIPT

    GenScript is a Hong Kong-based public company founded in 2002 with 6,165 employees providing biotechnology research services and products.

    TAKARA BIO INC.

    Takara Bio Inc is a Japan-based private company founded in 2002 with 1,779 employees specializing in biotechnology research tools and services.

    BIO-RAD LABORATORIES, INC.

    Bio-Rad Laboratories, Inc is a United States-based public company founded in 1952 with 7,450 employees manufacturing life sciences research and clinical diagnostics products.

    QIAGEN

    Qiagen is a Netherlands-based public company founded in 1984 with 5,500 employees providing molecular diagnostics and life sciences research solutions.

    CHARLES RIVER LABORATORIES

    Charles River Laboratories is a United States-based public company founded in 1947 with 19,000 employees providing preclinical and clinical laboratory services.

    CORNING INCORPORATED

    Corning Incorporated is a United States-based public company founded in 1851 with 67,200 employees manufacturing specialty glass and materials for life sciences applications.

    LONZA

    Lonza is a Switzerland-based public company founded in 1897 with 20,000 employees providing pharmaceutical and biotechnology manufacturing services.

    FUJIFILM HOLDINGS CORPORATION

    Fujifilm Holdings Corporation is a Japan-based public company founded in 1934 with 73,526 employees operating across imaging, pharmaceuticals, and life sciences sectors.

    SYNGENE INTERNATIONAL LIMITED

    Syngene International Limited is an India-based public company founded in 1993 with 6,692 employees providing drug discovery and development services.

    LGC LIMITED

    LGC Limited is a South Korea-based public company founded in 1947 with 14,019 employees operating in life sciences and analytical testing services.

    Reasons to Buy this Report

    • Market Size & Growth Projections : Access precise valuation data for the US market ($1,482.8M in 2026 growing to $2,235.7M by 2031) to benchmark investments, identify growth opportunities, and make informed strategic decisions in protein expression technologies.
    • Competitive Landscape Analysis : Understand the US biotechnology ecosystem, key market players, and competitive dynamics to identify partnership opportunities, acquisition targets, and market positioning strategies specific to the American biopharmaceutical sector.
    • Technology & Innovation Trends : Gain insights into emerging protein expression platforms, manufacturing innovations, and technological advancements driving the US market to stay ahead of competitors and align R&D investments with market demands.
    • Regulatory & Reimbursement Insights : Understand US FDA regulations, approval pathways, and reimbursement policies affecting protein-based therapeutics to navigate market entry strategies and optimize commercialization timelines for new products.
    • Investment & Expansion Strategy : Leverage comprehensive US market data to identify high-growth segments, optimal geographic locations for manufacturing facilities, and strategic investment opportunities in the expanding American biopharmaceutical landscape.

    Frequently asked questions

    What is the current size of the US protein expression market?

    The US protein expression market is valued at $1,482.8 million in 2026 and is expected to reach $2,235.7 million by 2031.

    What is the growth rate of the US protein expression market?

    The US protein expression market is growing at a compound annual growth rate (CAGR) of 8.6% from 2026 to 2031.

    Which expression systems dominate the US market?

    Mammalian and microbial expression systems are the dominant platforms in the US, driven by demand for monoclonal antibodies and recombinant proteins.

    What factors are driving growth in the US protein expression market?

    Key drivers include increased biopharmaceutical R&D, rising demand for cell-based therapies, regulatory support, and investment in manufacturing automation.

    Who are the primary end-users in the US protein expression market?

    Primary end-users include pharmaceutical companies, contract research organizations (CROs), biotechnology firms, and academic research institutions across the US.

    RESEARCH METHODOLOGY

    This study involved four major activities in estimating the current size of the protein expression market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

    Secondary Research

    Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology,. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global protein expression market, and the findings were validated through primary research.

    Primary Research

    In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

    Protein Expression Market Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The global size of the protein expression market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

    Protein Expression Market : Top-Down and Bottom-Up Approach

    Protein Expression Market Top Down and Bottom Up Approach

    Data Triangulation

    After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

    Market Definition

    The protein expression market encompasses the technologies, products, and services required for protein production and analysis. This market includes various expression systems (mammalian, bacterial, yeast, algal, insect, and cell-free), reagents and instruments for transfection and cloning, growth reagents for cell culture during translation, and reagents and kits for downstream processes such as purification and characterization. It serves industries such as pharmaceuticals, biotechnology, academic & research institutes, CROs & CDMOs, and other industrial users, supporting applications in drug discovery, therapeutic development, and biochemical research, as well as other industries such as food and beverages, cosmetics, and textiles, among others.

    Key Stakeholders

    • Protein Expression Instrument & Reagent Manufacturers
    • Suppliers of Expression Systems
    • National and regional research boards and organizations
    • Research & development companies
    • Clinical research organizations (CROs)
    • Contract Manufacturing Organizations (CMOs)
    • Biotechnology companies
    • Research laboratories & academic institutes
    • Market research & consulting firms
    • Regulatory bodies

    Report Objectives

    • To define, describe, and forecast the protein expression market by offering, type, workflow, scale of operation, protein modality, application, product end user, service end user, and region
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall protein expression market
    • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
    • To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia, United Arab Emirates, and the Rest of GCC) and the Rest of Middle East], and Africa
    • To profile the key players and analyze their market shares and core competencies
    • To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
    • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

    Customization Options

    With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe protein expression market, by country
    • Further breakdown of the Rest of Asia Pacific protein expression market, by country

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

    Segment Analysis

    • Cross-segment analysis

    Get the Full Protein Expression Market Report

    Full forecast, segment splits, and company analysis for all Protein Expression Market.

    Download Sample Pages Buy Report

    METHODOLOGY

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    Cite this Research
    DMCA.com Protection Status